Occurence of RAS reversion in metastatic colorectal cancer patients treated with bevacizumab

Background: A disappearance of RAS mutations in the plasma of about 50% of mCRCs (metastatic colorectal cancers) treated with bevacizumab-based chemotherapy has been reported. Our aim was to evaluate the same issue at tissue level. Materials and Methods: Using next-generation sequencing and real-tim...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncotarget
Egile Nagusiak: Epistolio, Samantha, Cefalì, Marco, Spina, Paolo, Molinari, Francesca, Movilia, Alessandra, Cergnul, Massimiliano, Mazzucchelli, Luca, De Dosso, Sara, Frattini, Milo, Saletti, Piercarlo
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Impact Journals LLC 2021
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8169066/
https://ncbi.nlm.nih.gov/pubmed/34084279
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.27965
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak